Viridian Therapeutics (VRDN)
Enters commercial stage with Lumvoa, an intravenous IGF-1R antibody for thyroid eye disease.
$21.31
vs last close−0.81 (−3.66%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
−$0.99
Revenue estimate
$4.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.81−$0.87−$1.00−$0.34−$1.08−$0.90−$1.05Pending
Estimate−$1.05−$0.95−$1.00−$0.82−$0.90−$1.06−$1.03−$0.99
Surprise+22.9%+8.4%0.0%+58.5%−20.0%+15.1%−1.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$72.0K$72.0K$75.0K$70.6M$132.0K$141.0K$284.0KPending
Estimate$50.0K$44.1K—$15.8M$18.4M$36.1K$56.4K$4.6M
Surprise+44.0%+63.3%—+348.1%−99.3%+290.8%+403.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.44 | — | — |
| Sep 2028 | $0.15 | — | — |
| Jun 2028 | −$0.05 | — | — |
| Mar 2028 | −$0.30 | — | — |
| Dec 2027 | −$0.12 | — | — |
| Sep 2027 | −$0.48 | — | — |
| Jun 2027 | −$0.61 | — | — |
| Mar 2027 | −$0.84 | — | — |
| Dec 2026 | −$0.97 | — | — |
| Nov 2026 | −$0.99 | — | — |
| Aug 2026 | −$1.03 | −$1.05 | −1.9% |
| May 2026 | −$1.06 | −$0.90 | +15.1% |
| Feb 2026 | −$0.90 | −$1.08 | −20.0% |
| Nov 2025 | −$0.82 | −$0.34 | +58.5% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Oct 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.44 | — | — | $237.1M | — | — | — |
| Sep 2028 | $0.15 | — | — | $200.0M | — | — | — |
| Jun 2028 | −$0.05 | — | — | $165.8M | — | — | — |
| Mar 2028 | −$0.30 | — | — | $124.5M | — | — | — |
| Dec 2027 | −$0.12 | — | — | $146.6M | — | — | — |
| Sep 2027 | −$0.48 | — | — | $95.6M | — | — | — |
| Jun 2027 | −$0.61 | — | — | $65.1M | — | — | — |
| Mar 2027 | −$0.84 | — | — | $43.1M | — | — | — |
| Dec 2026 | −$0.97 | — | — | $18.1M | — | — | — |
| Nov 4, 2026 | −$0.99 | — | — | $4.6M | — | — | — |
| Aug 6, 2026 | −$1.03 | −$1.05 | −1.9% | $56.4K | $284.0K | +403.9% | +6.8% |
| May 5, 2026 | −$1.06 | −$0.90 | +15.1% | $36.1K | $141.0K | +290.8% | +33.4% |
| Feb 26, 2026 | −$0.90 | −$1.08 | −20.0% | $18.4M | $132.0K | −99.3% | +1.9% |
| Nov 5, 2025 | −$0.82 | −$0.34 | +58.5% | $15.8M | $70.6M | +348.1% | +8.3% |
| Aug 6, 2025 | |||||||
| May 6, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 8, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 10, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 11, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 25, 2021 | |||||||
| Nov 10, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 11, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 13, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 14, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 11, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 24, 2017 | |||||||
| Oct 26, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 16, 2016 | |||||||
| Mar 16, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 12, 2015 |